Acumen Pharmaceuticals (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 37,755 Shares

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 37,755 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total value of $75,132.45. Following the completion of the sale, the chief executive officer directly owned 619,982 shares of the company’s stock, valued at $1,233,764.18. The trade was a 5.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Tuesday, January 6th, Daniel Joseph Oconnell sold 5,102 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.97, for a total value of $10,050.94.
• On Monday, January 5th, Daniel Joseph Oconnell sold 4,649 shares of Acumen Pharmaceuticals stock. The shares were sold at an average price of $1.97, for a total value of $9,158.53.

Acumen Pharmaceuticals Stock Up 1.5%

Shares of NASDAQ ABOS traded up $0.03 during midday trading on Wednesday, hitting $1.99. 220,171 shares of the stock traded hands, compared to its average volume of 159,170. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. Acumen Pharmaceuticals, Inc. has a one year low of $0.86 and a one year high of $2.46. The business has a 50 day moving average price of $1.96 and a two-hundred day moving average price of $1.67. The company has a market cap of $120.53 million, a PE ratio of -0.90 and a beta of 0.23.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.19. On average, equities analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Key Headlines Impacting Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Neutral Sentiment: No stated reason in filings — The disclosures show routine Form 4 sales but do not explain whether trades were pre‑planned or for personal liquidity/diversification; that ambiguity leaves market interpretation open.
• Negative Sentiment: CEO Daniel Joseph O’Connell sold a total of 47,506 shares across Jan. 5–7 (individual trades of 4,649; 5,102; and 37,755 shares), receiving about $94.3k in proceeds; the largest single trade (37,755 shares) was reported as a 5.74% reduction in his stake. Read More.
• Negative Sentiment: CFO Matt Zuga sold 14,905 shares over Jan. 5–7 (4,000; 5,100; 5,805), totaling roughly $29.4k in proceeds and small single‑trade ownership reductions (1.73%–2.61%). Read More.
• Negative Sentiment: COO Russell Barton sold 9,318 shares over Jan. 5–7 (4,000; 3,618; 1,700), raising about $18.4k and reducing his stake by small single‑trade percentages (1.32%–2.94%). Read More.
• Negative Sentiment: Insider Eric Siemers sold 10,834 shares on Jan. 5–6 (4,000; 6,834), for about $21.3k in proceeds and reported ownership reductions of ~2.35%–4.11% per trade. Read More.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ABOS shares. Bank of America dropped their price target on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Wall Street Zen raised Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a report on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.75.

Institutional Investors Weigh In On Acumen Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABOS. Invesco Ltd. increased its position in shares of Acumen Pharmaceuticals by 544.1% during the first quarter. Invesco Ltd. now owns 127,798 shares of the company’s stock valued at $141,000 after acquiring an additional 107,956 shares during the last quarter. AQR Capital Management LLC bought a new position in Acumen Pharmaceuticals in the 1st quarter valued at $46,000. Y Intercept Hong Kong Ltd bought a new position in Acumen Pharmaceuticals in the 2nd quarter valued at $291,000. Marshall Wace LLP purchased a new stake in shares of Acumen Pharmaceuticals during the 2nd quarter valued at $160,000. Finally, Qube Research & Technologies Ltd raised its stake in shares of Acumen Pharmaceuticals by 160.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company’s stock worth $67,000 after purchasing an additional 35,424 shares during the period. Hedge funds and other institutional investors own 71.01% of the company’s stock.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.